ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
20 announcements with these filters
Colinz Laboratories reported unaudited half-year profit of Rs 252.77 lakh to September 2026. The period includes a Rs 276.33 lakh exceptional gain on asset sale.
Colinz Laboratories scheduled a board meeting for October 29, 2026, to consider and approve the unaudited financial results for the quarter ended September 30, 2026.
The company filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.
Colinz Laboratories Ltd submitted a non-applicability declaration for Related Party Transaction disclosures for the quarter ended September 30, 2026. The company claims exemption under Regulation 15(2).
Colinz Laboratories held its 40th Annual General Meeting on September 22, 2026, where shareholders considered financial statements and director appointments.
Colinz Laboratories Ltd issued a Post Offer Advertisement for an Open Offer. The offer closed with only 6 shares tendered out of a proposed 6,54,966 shares.
Colinz Laboratories Limited has submitted its 40th Annual Report for the financial year 2025-26. The report includes notice for the Annual General Meeting scheduled for September 22, 2026.
Colinz Laboratories Ltd has issued the notice for its 40th Annual General Meeting scheduled for September 22, 2026. The agenda includes director re-appointments and auditor report adoption.
Saffron Capital Advisors filed a reminder advertisement for the open offer of Colinz Laboratories. The offer seeks to acquire up to 26% stake for ₹3.54 Crore.
The acquirers made an Open Offer to buy up to 6,54,966 shares of Colinz Laboratories Limited at ₹54 per share. This offer totals ₹3.54 Crore.
Colinz Laboratories Ltd reported revenue from operations of ₹1.2 Cr (-25.0% YoY) and net profit of ₹2.4 Cr (+2300.0% YoY) for Q1 FY27.
Colinz Laboratories has scheduled a board meeting for July 30, 2026, to consider quarterly financial results and other corporate matters.
Colinz Laboratories faces a mandatory open offer for 26% of its shares. The offer, valued at Rs.3.54 Crore, is led by Saffron Capital Advisors on behalf of the acquirers.
Colinz Laboratories Ltd states related party transaction disclosures are exempt for Q2 2026 under SEBI LODR 23(9). The filing complies with exemption under Regulation 15(2)(a).
Colinz Laboratories completed the sale of its factory and land to Hilsun Foods. The total consideration received for the transaction is ₹4 Crore.
Anajuna Duggar and others launched an open offer for Colinz Laboratories Ltd. The offer aims to acquire 26% stake at Rs. 54 per share.
Colinz Laboratories responded to a BSE query on share price movement, stating no UPSI exists. The price move is attributed to market conditions, not company actions.
Mr. Padam Dugar and PACs acquired a 15.01% stake in Colinz Laboratories through an off-market transaction. This significant non-promoter entry impacts the company's shareholding structure.
Padam Dugar and associates acquired a 15.01% stake in Colinz Laboratories through an off-market transaction. This significant acquisition increases their total holding to 3,78,000 shares.
Promoter Vijaya Mani sold 3,78,000 shares of Colinz Laboratories via an off-market transaction. The sale reduced the promoter's stake from 49.56% to 34.56%.